CHEMOMAB THERAPEUTICS LTD. - AMERICAN DEPOSITARY

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

24 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

18 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

02 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

25 مارس 2024 07:06:46 بحسب Nasdaq GlobeNewswire